Recent News

Can a Liquid Biomarker Augment Early Screening for Lung Cancer?

ESMO 2022: ADAURA Update on Adjuvant Osimertinib in Completely Resected EGFR-Mutated NSCLC

ESMO 2022: Interim Results From DESTINY-Lung02 Trial of T-DXd in NSCLC

FDA Grants Regular Approval to Selpercatinib in Locally Advanced or Metastatic RET Fusion–Positive NSCLC

ESMO 2022: Long-Term Follow-up of Overall Survival From the POSEIDON Lung Cancer Trial

ESMO 2022: Outcomes With Pembrolizumab and PD-L1 Expression in Resected NSCLC

ESMO 2022: 5-Year Survival Update on Pembrolizumab Plus Chemotherapy for Squamous NSCLC

University of Chicago Joins Research Initiative to Develop AI Tools in Lung Cancer Treatment

ESMO 2022: 5-Year Update From KEYNOTE-189 on Pembrolizumab Plus Chemotherapy in NSCLC

Bevacizumab for Advanced NSCLC: DNA Methylation Signature as a Predictive Biomarker?

WCLC 2022: JAVELIN Lung 100 Trial of Avelumab Versus Chemotherapy for Advanced NSCLC

WCLC 2022: Radon Exposure and Prevalence of Molecular Alterations in NSCLC Across Europe

Pathogenic Germline Variants in Patients With Lung Cancer

WCLC 2022: Nonregional Lymph Nodes and Prognosis in Stage IV NSCLC

WCLC 2022: Early Data on Sotorasib Plus an SHP2 Inhibitor in KRAS-Mutated NSCLC

WCLC 2022: SHAWL Study Focuses on Sexual Dysfunction in Women With Lung Cancer

WCLC 2022: Noninferiority Trial of Lobar or Sublobar Resection for Peripheral NSCLC

WCLC 2022: Interim Analysis of Overall Survival With Atezolizumab in Resected NSCLC From IMpower010

T-DXd Receives Accelerated Approval From the FDA for Treatment of HER2-Mutant NSCLC

Capmatinib Granted Regular Approval by the FDA in Treatment of Metastatic NSCLC

WCLC 2022: Biomarker-Directed Study of Treatment Options in NSCLC After Immunotherapy

WCLC 2022: NELSON Trial Protocol Versus NLST Protocol in Lung Cancer Screening

COVID-19 Vaccination in Immune Checkpoint Inhibitor–Treated Patients With Lung Cancer in Japan

Overall Survival Update From NADIM Trial: Neoadjuvant Nivolumab Plus Chemotherapy for NSCLC

Use of Liquid Biopsies in Managing EGFR-Mutant and Resistant Lung Cancers

IFCT-1803 LORLATU Cohort Evaluates Lorlatinib in Advanced ALK-Rearranged NSCLC

Does Esophageal-Sparing Radiotherapy Reduce the Risk of Esophagitis in Advanced NSCLC?

CodeBreaK 201 Focuses on Sotorasib in First-Line Treatment of Stage IV NSCLC

Neoadjuvant Selpercatinib Under Study in Resectable RET Fusion–Positive NSCLC

Neoadjuvant Nivolumab Plus Chemotherapy in Advanced Resectable NSCLC

Penn Medicine Receives $9 Million Award From NCI to Study Intraoperative Molecular Imaging

Pooled Analysis of Appropriate NSCLC Populations for First-Line Immunotherapy Plus Chemotherapy

Cabozantinib Plus Atezolizumab in Advanced Non–Small Cell Lung Cancer

ASCO 2022: Mobocertinib Versus Amivantamab-vmjw in Treatment of EGFR-Mutated NSCLC

ASCO 2022: Eftilagimod Alpha Plus Pembrolizumab in NSCLC

ASCO 2022: Amivantamab-vmjw Under Study in NSCLC With Primary MET Exon 14 Skipping Mutation

Baseline Body Mass Index and Outcomes in Chemoimmunotherapy-Treated Lung Cancer

Does Long-Term Exposure to Wildfires Increase the Risk for Lung Cancer?

ASCO 2022: Expanded Cohort Update on Larotrectinib for NTRK Fusion–Positive Lung Cancer

ASCO 2022: How Has Low-Dose Chest CT Screening Impacted the Incidence of Lung Cancer?

FDA Brief: Application Accepted for Pembrolizumab as Adjuvant Therapy Early-Stage NSCLC

ASCO 2022: CHRYSALIS-2 Update on Amivantamab-vmjw Plus Lazertinib in NSCLC

ASCO 2022: Pathologic Regression and Event-Free Survival With Nivolumab Plus Chemotherapy for NSCLC

ASCO 2022: 3-Year Trial Update on Nivolumab Plus Ipilimumab and Chemotherapy for Metastatic NSCLC

ASCO 2022: Second-Line Pembrolizumab Plus Ramucirumab in Advanced NSCLC

ASCO 2022: Adagrasib Under Study in Advanced KRAS G12C–Mutated NSCLC

City-Wide Approach to Lung Cancer Screening: From Three Philadelphia Health Systems

Gender and Racial Disparities in U.S. Lung Cancer Mortality: A 10-Year Analysis

Do CT Assessments of Emphysema Suggest Higher Odds of Lung Cancer?

Is Vascular Pruning Associated With Poorer Clinical Outcomes in Early-Stage Lung Cancer?

Do Patients at High Risk for Lung Cancer Experience Delays in Follow-up Screening?

Novel CRISPR Approach May Uncover Regulators of Lung Cancer Development

Newly Identified HER2 Mutations in Non–Small Cell Lung Cancer Focus on Exons 18 and 19

IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer

Can MCT4 Blockade Counter Resistance to Immunotherapy in LKB1-Mutant Lung Cancer?

Polymorphisms in Immune Checkpoint Proteins and Response to Immunotherapy

Preclinical Rationale for Combining KRAS and MCL1 Inhibitors in KRAS-Mutant Lung Cancer

AACR 2022: Overall Survival Update With Sotorasib in KRAS-Mutated Lung Cancer

AACR 2022: Nivolumab Plus Chemotherapy for Resectable Lung Cancer in Phase III CheckMate 816 Trial

AACR 2022: Neoadjuvant Durvalumab Alone or in Combination for Early-Stage Lung Cancer

Fam-Trastuzumab Deruxtecan-nxki Granted Priority Review in HER2-Mutant NSCLC

Update From LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

AACR 2022: Circulating Tumor DNA–Based Monitoring After Surgery for NSCLC

AACR 2022: Could Estrogen Derivatives Be Linked to Lung Cancer in Never-Smokers?

AACR 2022: Can Somatic Mutations and Ancestry Provide Risk Clues in Latin American Patients?

Targeting HER2 Mutations in NSCLC With Triplet Therapy

Does Adding Radiotherapy to Immunotherapy Improve Outcomes in Metastatic NSCLC?